Sarepta Therapeutics Inc SRPT:NASDAQ

Last Price$85.36NASDAQ Closing Price as of 4:00PM ET 9/19/19

Today's Change+1.69(2.02%)
Bid (Size)$85.25 (1)
Ask (Size)$86.88 (1)
Day Low / High$81.63 - 85.92
Volume1.2 M

View Biotechnology IndustryPeer Comparison as of 09/19/2019


Sarepta Therapeutics Inc ( NASDAQ )

Price: $85.36
Change: +1.69 (2.02%)
Volume: 1.2 M
4:00PM ET 9/19/2019

ACADIA Pharmaceuticals Inc ( NASDAQ )

Price: $41.67
Change: -0.49 (1.16%)
Volume: 2.0 M
3:59PM ET 9/19/2019

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A

bluebird bio Inc ( NASDAQ )

Price: $106.08
Change: -1.36 (1.27%)
Volume: 376.2 K
3:59PM ET 9/19/2019

Moderna Inc ( NASDAQ )

Price: $17.90
Change: +0.12 (0.67%)
Volume: 5.9 M
4:00PM ET 9/19/2019

Read more news Recent News

Insider Trends: 90-Day Buying Trend Added to with Insider Purchase of Sarepta Therapeutics Stock
8:02AM ET 9/16/2019 MT Newswires

On Sep 12, 2019, Richard Barry, Director, reported a purchase of 5,000 shares in Sarepta Therapeutics (SRPT) for $437,455. Barry, subsequent to the...

Insider Trends: Insider Buying Continued with Purchase of Sarepta Therapeutics Stock
2:20PM ET 9/09/2019 MT Newswires

On Sep 09, 2019, Director, Michael W Bonney, reported a purchase of 2,000 shares in Sarepta Therapeutics (SRPT) for $173,480. After the Form 4 filing with...

Insider Trends: Insider at Sarepta Therapeutics Buys Stock, Exercises Options, Extends 90-Buy Trend
2:14PM ET 9/06/2019 MT Newswires

On Sep 05, 2019, M Kathleen Behrens, Director, exercised 5,000 in the money options for shares in Sarepta Therapeutics (SRPT) at a net purchase price of...

Analyst Actions: Needham Cuts Sarepta Therapeutics' Price Target to $170 From $196, Maintains Buy Rating
8:49AM ET 8/21/2019 MT Newswires

Sarepta Therapeutics' (SRPT) average rating among analysts is a buy, with an average price target of $186. Price: 102.18, Change: +0.11, Percent Change:...

Company Profile

Business DescriptionSarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA. View company web site for more details
Address215 First Street
Cambridge, Massachusetts 02142
Number of Employees499
Recent SEC Filing09/16/20194
President, Chief Executive Officer & DirectorDouglas S. Ingram
Chief Financial & Business Officer, Executive VPSandesh Mahatme
Chief Scientific OfficerGuriqbal S. Basi
Chief Medical Officer & Senior Vice PresidentGilmore O'Neill

Company Highlights

Price Open$83.72
Previous Close$83.67
52 Week Range$81.33 - 165.87
Market Capitalization$6.3 B
Shares Outstanding74.3 M
SectorHealth Technology
Next Earnings Announcement10/23/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$6.33
Beta vs. S&P 500N/A
Revenue$301.0 M
Net Profit Margin-165.52%
Return on Equity-55.37%

Analyst Ratings as of 09/12/2019

Consensus RecommendationConsensus Icon
Powered by Factset